Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Analyst consensus and Net cash floor.
ACCE opinionTaysha Gene Therapies Inc. Common Stock (TSHA)
Fair value
Not available
ACCE price target
$4.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 12 Oct 2026, 00:00 CEST.
Price used: $3.96 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
35
out of 100
Analysts
100% buy
13 covering
P/E
0.0x
forward 0.0x
1-year return
-19.8%
Dividend yield
0.00%
Taysha Gene Therapies Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Taysha Gene Therapies is a clinical-stage biotech developing AAV-based gene therapies for rare neurological diseases, with its lead programs aimed at Rett syndrome and other monogenic CNS disorders. The moat rests on its capsid and vector engineering platform and on the fact that few companies have advanced single-dose CNS gene therapies this far into development. Its revenue jumped 171% year over year, but that growth comes from collaboration and licensing income on a small base, and the operating margin of roughly -2,790% shows how far the company remains from product sales. The near-term catalysts are pivotal data and regulatory interactions for the Rett program, which will determine whether the platform converts into a filing. At a $1.2B market cap with ROE of -47% and a 37/100 score, the valuation leans on that clinical readout rather than current fundamentals, so the case merits a deeper look only if the reader is comfortable underwriting binary trial and regulatory risk.